Eisai, UCL extend neuroscience alliance to 2030

Five-year renewal backs new drug discovery projects for Alzheimer’s, Parkinson’s and other brain diseases, with longevity in sight. Most collaborations between universities and pharma companies are built around a single goal to answer one research question, develop one technology or test one drug candidate. Once the project ends (or the funding dries up), the partnership […] The post Eisai, UCL extend neuroscience alliance to 2030 appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.